1. Pink Sheet

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

 
• By Bridget Silverman

As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.

'Dynamic Changes' In Pneumococcal Disease Incidence are Anticipated. • Source: Shutterstock

The active pipeline of new, higher-valent pneumococcal vaccine candidates promises to keep the US Centers for Disease Control and Prevention’s already notoriously confusing guidelines at the center of deliberations by its Advisory Committee for Immunization Practices.

Key Takeaways

  • The CDC’s Advisory Committee for Immunization Practices is preparing to vote on recommendations for Merck’s 21-valent V116 pneumococcal vaccine candidate at its 26-28 June meeting, less than two weeks after the vaccine’s 17 June FDA user fee goal.

The committee now is gearing up for a vote at its 26-28 June meeting on recommendations for Merck &...

More from Vaccines

More from Pink Sheet

Price Inflation Rebates: Biden Policies Add Teeth To Trump’s Pharma Tariff Threat

 
• By Cathy Kelly

Companies with significant exposure to Medicare and Medicaid have fewer options for passing along higher costs to consumers because of price controls in the programs.

US FDA Acting Drug Center Chief Corrigan-Curay Retiring, Senior Staff Remake Continues

 
• By Derrick Gingery

The news coincides with rumors that Commissioner Martin Makary soon will name a new Center for Drug Evaluation and Research director.

EU Pharma Reform: Lawyers Unpack Diverging Visions For Innovation

 
• By Eliza Slawther

There are now three draft versions of the legislative text that will overhaul the framework governing pharmaceuticals in the EU. Lawyers explain how the approaches proposed by the European Commission, European Parliament and Council of the EU differ and highlight implications for industry.